CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Revenues
Total revenues	$ 6,147,283	$ 2,671,542	$ 10,312,989	$ 4,287,683
Total cost of product and clinical laboratory service revenues	3,658,798	940,568	6,715,366	1,456,349
Gross profit	2,488,485	1,730,974	3,597,623	2,831,334
Operating expenses:
Selling, general and administrative	3,412,777	3,091,227	8,074,950	6,400,881
Research and development	1,070,041	955,738	2,150,137	1,719,546
Total operating expenses	4,482,818	4,046,965	10,225,087	8,120,427
LOSS FROM OPERATIONS	(1,994,333)	(2,315,991)	(6,627,464)	(5,289,093)
Other (expense) income:
Interest income, net	5,540	13,841	5,813	8,403
Loss on extinguishment of debt	0	0	0	(1,774,662)
Gain on extinguishment of notes payable	0	839,945	0	839,945
Transaction cost allocated to warrant liabilities	(391,335)	0	(391,335)	0
Unrealized gain on change in fair value of the Common Warrants	782,500	0	782,500	0
Other expense, net	(162,169)	(54,873)	(250,222)	(108,733)
Loss before provision for income taxes	(1,759,797)	(1,517,078)	(6,480,708)	(6,324,140)
Provision for income taxes	0	0	0	0
NET LOSS	(1,759,797)	(1,517,078)	(6,480,708)	(6,324,140)
Less: Net loss (income) attributable to noncontrolling interest	1,112	278	257	(2,216)
NET LOSS attributable to Applied DNA Sciences, Inc.	(1,758,685)	(1,516,800)	(6,480,451)	(6,326,356)
Deemed dividend related to warrant modifications	110,105	0	110,105	0
NET LOSS attributable to common stockholders	$ (1,868,790)	$ (1,516,800)	$ (6,590,566)	$ (6,326,356)
Net loss per share attributable to common stockholders - basic	$ (0.23)	$ (0.21)	$ (0.85)	$ (1.00)
Net loss per share attributable to common stockholders - diluted	$ (0.23)	$ (0.21)	$ (0.85)	$ (1.00)
Weighted average shares outstanding - basic	8,084,680	7,235,031	7,783,747	6,341,590
Weighted average shares outstanding - diluted	8,084,680	7,235,031	7,783,747	6,341,590
Product revenues
Revenues
Total revenues	$ 408,351	$ 965,110	$ 1,234,662	$ 1,515,207
Total cost of product and clinical laboratory service revenues	469,981	367,331	904,910	638,019
Service revenues
Revenues
Total revenues	248,690	151,552	387,963	444,826
Clinical laboratory service revenues
Revenues
Total revenues	5,490,242	1,554,880	8,690,364	2,327,650
Total cost of product and clinical laboratory service revenues	$ 3,188,817	$ 573,237	$ 5,810,456	$ 818,330